A Randomized Phase III Clinical Trial for the Addition of Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response

Disease Sites:

Prostate

Staging:

Phase III

Age Group:

Adults

Therapies:

Chemotherapy - cytotoxic

Drugs:

Docetaxel (Taxotere)

Principal Investigator(s):

Schaffer, Kerry

Scope:

International

Participating Institutions:

Vanderbilt University

Open Date:

09-23-2025

Trial Type:

Treatment

Protocol ID:

ALLUROCCTGPR26

National Clinical Trial ID:

NCT06592924

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available